http://www.mmm-online.com/orphan-drug/topic/12996/ Articles tagged with Orphan Drug from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no Why executives evaluating biotech acquisitions shouldn't overlook the cultural dimension: A new paper finds a link to revenue performance. http://www.mmm-online.com/culture-of-innovation-has-a-sales-value-study-says/article/293086/ Mon, 13 May 2013 15:15:03 GMT Why executives evaluating biotech acquisitions shouldn't overlook the cultural dimension: A new paper finds a link to revenue performance. MMM Aegerion's Juxtapid is first to market for treating the ultrarare inherited cholesterol condition HoFH, or homozygous familial hypercholesterolemia. http://www.mmm-online.com/drug-for-ultrarare-lipid-disorder-okd-by-fda/article/273972/ Wed, 26 Dec 2012 20:12:38 GMT Aegerion's Juxtapid is first to market for treating the ultrarare inherited cholesterol condition HoFH, or homozygous familial hypercholesterolemia. MMM Notes to the advisory committee indicate that recycled data has perceived weak spots. http://www.mmm-online.com/fda-committee-set-to-review-chronic-fatigue-drug/article/273345/ Wed, 19 Dec 2012 18:10:17 GMT Notes to the advisory committee indicate that recycled data has perceived weak spots. MMM Corcept Therapeutics said its Cushing's syndrome drug will be launched three weeks earlier than expected. http://www.mmm-online.com/company-news-corcept-therapeutics-and-daiichi-sankyo/article/233371/ Fri, 23 Mar 2012 14:35:58 GMT Corcept Therapeutics said its Cushing's syndrome drug will be launched three weeks earlier than expected. MMM Shire has pulled its drug, Replagal, from FDA review. The company was set to go before the agency next month, but preliminary talks indicated the FDA was going to require more testing. http://www.mmm-online.com/shire-exits-fabrys-market-citing-costs-as-fda-weighs-more-research/article/232195/ Thu, 15 Mar 2012 18:56:02 GMT Shire has pulled its drug, Replagal, from FDA review. The company was set to go before the agency next month, but preliminary talks indicated the FDA was going to require more testing. MMM Specialty drug company ViroPharma teamed with several medical societies on the launch of a program designed to unite specialists treating patients with the orphan condition hereditary angioedema (HAE). http://www.mmm-online.com/company-news-viropharma-and-dime/article/205980/ Thu, 23 Jun 2011 17:51:44 GMT Specialty drug company ViroPharma teamed with several medical societies on the launch of a program designed to unite specialists treating patients with the orphan condition hereditary angioedema (HAE). MMM